Literature DB >> 28347880

Impact of Surgical Route in Influencing the Risk of Lymphatic Complications After Ovarian Cancer Staging.

Giorgio Bogani1, Chiara Borghi2, Antonino Ditto1, Mauro Signorelli1, Fabio Martinelli1, Valentina Chiappa1, Cono Scaffa1, Stefania Perotto1, Umberto Leone Roberti Maggiore3, Luca Montanelli4, Violante Di Donato5, Carmelo Infantino6, Domenica Lorusso7, Francesco Raspagliesi1.   

Abstract

Lymphatic complications are a common occurrence after staging surgery for early-stage ovarian cancer (eEOC). We investigated whether the introduction of minimally invasive surgery influences the risk of developing lymphoceles and lymphorrhea in patients undergoing staging for eEOC. For this purpose, data of consecutive patients affected by eEOC undergoing staging surgery between January 1980 and January 2016 were retrospectively reviewed, and a systematic review and meta-analysis was performed. This systematic review was registered in the International Prospective Register of Systematic Review. Among 341 patients included in the present study, 47 severe postoperative complications occurred (13.7%), including 40 lymphatic complications: 31 symptomatic lymphoceles (9%) and 9 cases of lymphorrhea (2.6%), respectively. Laparoscopic staging correlated with a lower risk of developing any severe lymphatic complications in comparison with open surgery (p = .02). In particular, the laparoscopic approach and para-aortic node involvement were associated with a trend toward lower lymphoceles (odds ratio, .13; 95% confidence interval, .07-2.20; p = .05) and a trend toward higher risk of lymphorrhea developing (odds ratio, 4.02; 95% confidence interval, .93-17.3; p = .06), respectively. In conclusion, the implementation of a minimally invasive approach might result in a slight reduction of lymphatic complications after eEOC staging.
Copyright © 2017 AAGL. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Laparoscopy; Lymphoceles; Lymphorrhea; Ovarian cancer; Staging

Mesh:

Year:  2017        PMID: 28347880     DOI: 10.1016/j.jmig.2017.03.014

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  6 in total

1.  Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.

Authors:  Koji Matsuo; Erica J Chang; Shinya Matsuzaki; Rachel S Mandelbaum; Kazuhide Matsushima; Brendan H Grubbs; Maximilian Klar; Lynda D Roman; Anil K Sood; Jason D Wright
Journal:  Gynecol Oncol       Date:  2020-05-10       Impact factor: 5.482

Review 2.  Is It the Time for Laparoscopic Management of Early-stage Ovarian Malignancies?

Authors:  Tanitra Tantitamit; Chyi-Long Lee
Journal:  Gynecol Minim Invasive Ther       Date:  2018-08-23

3.  Risk factors, microbiology and management of infected lymphocyst after lymphadenectomy for gynecologic malignancies.

Authors:  Xuegong Ma; Yingmei Wang; Aiping Fan; Mengting Dong; Xin Zhao; Xuhong Zhang; Fengxia Xue
Journal:  Arch Gynecol Obstet       Date:  2018-09-29       Impact factor: 2.344

4.  The impact of lymph node dissection on survival in patients with clinical early-stage ovarian cancer.

Authors:  Ting Deng; Qidan Huang; Ting Wan; Xiaoling Luo; Yanling Feng; He Huang; Jihong Liu
Journal:  J Gynecol Oncol       Date:  2021-05       Impact factor: 4.401

5.  Efficacy and Safety of Minimally Invasive Surgery Versus Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A Systematic Review and A Meta-Analysis.

Authors:  Siyuan Zeng; Yongai Yu; Yuemei Cui; Bing Liu; Xianyu Jin; Zhengyan Li; Lifeng Liu
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

6.  Isolated tumour cells in a sentinel lymph node of apparent early-stage ovarian cancer: Ultrastaging of all other 27 lymph nodes.

Authors:  Stefano Uccella; Mariachiara Bosco; Anna Fagotti; Simone Garzon; Pier Carlo Zorzato; Raffaele Tinelli; Elena Biletta; Irene Porcari; Daniele Liscia; Giovanni Scambia; Massimo Franchi
Journal:  Gynecol Oncol Rep       Date:  2022-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.